BioInvent: Key Takeaways from Yesterday’s KOL Event - Redeye

Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical development updates for its two lead blood cancer candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB). Below is our analysis of the key discussion points based on the expert insights shared yesterday.

Länk till analysen i sin helhet: https://www.redeye.se/research/1172082/bioinvent-key-takeaways-from-yesterdays-kol-event?utm_source=finwire&utm_medium=RSS